Group 1 - The core point of the announcement is that shareholders Qi Lu Investment and Qingsong Investment plan to reduce their holdings in Jinkai Biotechnology (301509) by a total of up to 361.2 million shares, which represents 3% of the company's total share capital [1] - Qi Lu Investment intends to reduce its stake by up to 120.4 million shares through centralized bidding, accounting for 1% of the total share capital, and by up to 240.8 million shares through block trading, accounting for 2% of the total share capital [1] - Qingsong Investment plans to reduce its stake by up to 120.4 million shares through centralized bidding, also representing 1% of the total share capital [1] Group 2 - The reduction period for these share sales will be within three months starting from fifteen trading days after the announcement date [1]
金凯生科：启鹭投资和青松投资拟分别减持3%和1%股份